Commentary|Videos|March 13, 2025

Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC

Author(s)Daniel J. George, MD, Matthew Smith, MD, PhD

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.

Episodes in this series

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.

EP. 1 The Evolution of Treatment in Metastatic Hormone-Sensitive Prostate Cancer

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.

EP. 2 Data From an Age-Related Subgroup Analysis of the ARASENS Trial in mHSPC

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.

EP. 3 Outcomes by Disease Volume: A Subgroup Analysis of the ARANOTE Trial in mHSPC

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.

EP. 4 Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.

EP. 5 Ongoing Research to Watch in Prostate Cancer in 2025 and Beyond

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.

EP. 6 Key Prostate Cancer Updates to Emerge From ASCO GU 2025

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

September 28th, 2026

Calculating the Real Cost of False Positive Findings in Cancer Screening

Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.

Trending on OncLive

Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI

FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer

Calculating the Real Cost of False Positive Findings in Cancer Screening

China's NMPA Approves Pirtobrutinib Across CLL

Dose Intensity Anchors JAK Inhibitor Selection as Combinations and Targeted Agents Expand Options in Myelofibrosis